» Articles » PMID: 16305822

Stimulation of Oncogenic Metabotropic Glutamate Receptor 1 in Melanoma Cells Activates ERK1/2 Via PKCepsilon

Overview
Journal Cell Signal
Date 2005 Nov 25
PMID 16305822
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Metabotropic glutamate receptor 1 (Grm1, formerly mGluR1) is a G protein coupled receptor (GPCR) normally expressed and functional in the central nervous system. Studies of our transgenic mouse melanoma model (TG-3) revealed that ectopic expression of Grm1 in melanocytes is sufficient to induce melanoma development in vivo [P.M. Pollock, K. Cohen-Solal, R. Sood, J. Namkoong, J.J. Martino, A. Koganti, H. Zhu, C. Robbins, I. Makalowska, S.S. Shin, Y. Marin, K.G. Roberts, L.M. Yudt, A. Chen, J. Cheng, A. Incao, H.W. Pinkett, C.L. Graham, K. Dunn, S.M. Crespo-Carbone, K.R. Mackason, K.B. Ryan, D. Sinsimer, J. Goydos, K.R. Reuhl, M. Eckhaus, P.S. Meltzer, W.J. Pavan, J.M. Trent, S. Chen, Nat. Genet. 34 (2003) 108-112.]. We have established and characterized several cell lines in vitro from independent mouse melanoma tumors [Y.E. Marín, J. Namkoong, S.S. Shin, J. Raines, K. Degenhardt, E. White, S. Chen, Neuropharmacol. 49 (2005) 70-79.]. These cell lines are useful tools in the studies of signaling events that may be mediated by Grm1 in transformed melanocytes. Here we show that stimulation of Grm1 by l-quisqualate, a group I metabotropic glutamate receptor agonist, results in inositol triphosphate (IP3) accumulation, and the activation of ERK1/2 in these cell lines. IP3 accumulation and ERK1/2 activation were inhibited by pretreatment of the tumor cells with a Grm1-specific antagonist (LY367385) or by dominant negative mutants of Grm1, demonstrating the specificity of these events. We also show that ERK1/2 activation by Grm1 was PKC-dependent, but cAMP and PKA-independent. PKCepsilon was shown to play a pivotal role in Grm1-mediated ERK1/2 phosphorylation. Insights into the signaling cascades mediated by Grm1 in melanoma cells may aid in the identification of key molecular targets for the future design of combined therapies for melanoma.

Citing Articles

Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance.

Fateeva A, Eddy K, Chen S Cancers (Basel). 2024; 16(8).

PMID: 38672652 PMC: 11049326. DOI: 10.3390/cancers16081571.


Assessing Longitudinal Treatment Efficacies and Alterations in Molecular Markers Associated with Glutamatergic Signaling and Immune Checkpoint Inhibitors in a Spontaneous Melanoma Mouse Model.

Eddy K, Gupta K, Eddin M, Marinaro C, Putta S, Sauer Jr J JID Innov. 2024; 4(2):100262.

PMID: 38445232 PMC: 10914525. DOI: 10.1016/j.xjidi.2024.100262.


A At-labelled mGluR1 inhibitor induces cancer senescence to elicit long-lasting anti-tumor efficacy.

Xie L, Zhang L, Hu K, Hanyu M, Zhang Y, Fujinaga M Cell Rep Med. 2023; 4(4):100960.

PMID: 37003259 PMC: 10140459. DOI: 10.1016/j.xcrm.2023.100960.


Protein Kinase C (PKC) Isozymes as Diagnostic and Prognostic Biomarkers and Therapeutic Targets for Cancer.

Kawano T, Inokuchi J, Eto M, Murata M, Kang J Cancers (Basel). 2022; 14(21).

PMID: 36358843 PMC: 9658272. DOI: 10.3390/cancers14215425.


Implications of a Neuronal Receptor Family, Metabotropic Glutamate Receptors, in Cancer Development and Progression.

Eddy K, Eddin M, Fateeva A, Pompili S, Shah R, Doshi S Cells. 2022; 11(18).

PMID: 36139432 PMC: 9496915. DOI: 10.3390/cells11182857.